Novartis: India's IP record steering R&D to China; Xenome struggles to regroup after trial failure;

@FierceBiotech: Will the biotech dealmaking lull extend through the rest of the year? More | Follow @FierceBiotech

@JohnCFierce: Novartis lashes out at India's patent rulings, says country is losing R&D. But India clearly doesn't care about R&D. More | Follow @JohnCFierce

@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. Article | Follow @RyanMFierce

@EmilyMFierce: Inovio vaccine kills malaria, boosts immune response in animals. Story | Follow @EmilyMFierce

> Novartis ($NVS) India Vice Chairman and Managing Director Ranjit Shahani laid out a threatening message to the country's lawmakers, noting that India's track record on drug IP was costing the subcontinent significant R&D investments by Big Pharma. "What we certainly would like to see is an ecosystem that fosters innovation and fast-track courts to hear and decide cases involving IPR. China has drawn all the leading global companies to invest in R&D there while India has not. That itself should serve as food for thought," he said. Story

> Australia's Xenome is trying to regroup after the clinical failure of its experimental drug for postsurgery pain. Company execs say they'll need a partner in order to refocus their work. Story

Medical Device News

@FierceMedDev: Special report: Device-tax worries aside, major med tech mostly added jobs in 2012. Feature | Follow @FierceMedDev

@DamianFierce: How can early-phase CROs brave a tough market? We asked two of the biggest. Editor's corner | Follow @DamianFierce

@MarkHFierce: Orthofix is in trouble again, this time for not filing its financials on time. Press release | Follow @MarkHFierce

@MichaelGFierce: Last week's Chutes & Ladders roundup: Pharma veteran Jeffrey Jonas takes top spot at Sage & more in biotech/pharma hirings. More | Follow @MichaelGFierce

> Abbott closes $250M deal for eye surgery biz. Article

> St. Jude snags Endosense for up to $331M. Report

> Cigna policy change risks hammering Myriad's Dx bottom line. Story

Pharma News

@FiercePharma: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Article | Follow @FiercePharma

@EricPFierce: India to consider putting handcuffs on foreign investment to protect domestic generics market. Story | Follow @EricPFierce

@CarlyHFierce: Merck stops selling Zilmax to study livestock drug's safety; the drug added $159M to sales in 2012. News | Follow @CarlyHFierce

> FTC asks to file brief in Effexor case, testing Supreme Court's pay-for-delay ruling. More

> Fresenius inks deal for 51% stake in Indonesian drugmaker. Item

CRO News

> Quintiles buying Novella with eye on emerging biotechs. More

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Article

> Risk-based monitoring could be a boon to CROs. Item

> Boehringer pulls plug on VA commercial plant. Story

> Express Scripts sells CRO biz to private equity outfit. More

> WuXi ratchets up expectations after banner quarter. News

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Report

Biotech IT News

> RTI wins NIH support to advance web-based toolkit for genetics research. News

> India's InterpretOmics scores $1.6M round to fuel bioinformatics biz. Report

> Pfizer taps online marketplace for outsourcing research. Story

> FDA's former IT boss nails down industry gig. More

> Certara, provider of drug research software, buys Michigan rival. Article

And Finally… Michigan State's Michael Feig has been studying how natural DNA repair can prevent cancer. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.